Dimerix Stock

Dimerix Stock-Based Compensation

The Stock-Based Compensation (SBC) of Dimerix (DXB.AX) as of Aug 7, 2026 is 898,800.00 AUD. In the previous year, Stock-Based Compensation (SBC) was 1.41 M AUD — a change of -36.21% (lower).

Stock-Based Compensation

898,800.00AUD

YoY

-36.21%

Last updated:

Stock-Based Compensation (SBC) of Dimerix is 2026 898,800.00 AUD. Stock-Based Compensation (SBC) of Dimerix was 2025 1.41 M AUD. It decreases by -36.21% lower compared to the previous year.
Access this data via the Eulerpool API

Dimerix Stock analysis

What does Dimerix do? Dimerix Ltd is an Australian biotechnology company specializing in the development of innovative therapies for various medical needs. Their business model is based on identifying new targets for drug development, often through collaborations with other biotech or pharmaceutical companies. Dimerix focuses on cancer therapy, utilizing their innovative platform technology to identify and test a variety of drug candidates. They also have a pipeline of medications for kidney and lung diseases, as well as inflammation and pain. Dimerix actively seeks partnerships with other companies and research institutions to bring innovative therapies to market. One of their key products, DMX-200, is currently in phase II clinical trials for the treatment of kidney diseases and has shown promising results. Overall, Dimerix is well-positioned to continue bringing successful therapies to market in the future. Dimerix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Dimerix stock

Stock-Based Compensation (SBC) of Dimerix is 898,800.00 AUD in 2026.

Stock-Based Compensation (SBC) of Dimerix changed from 1.41 M AUD to 898,800.00 AUD, representing a -36.21% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) Dimerix since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s Dimerix historically and in real time.

Access this data via the Eulerpool API

Cash Flow — Dimerix

All Key Metrics — Dimerix